The First Synthetic Peptide That Replaces Animal Lung Surfactant for Breathing Problems

Review of published research on KL4 (sinapultide) structure, function, and clinical application as a synthetic lung surfactant, including molecular characterization studies using biophysical methods to understand peptide-lipid interactions.

Premature babies and patients with acute lung injury need surfactant therapy to keep their lungs from collapsing. Current treatments use surfactant extracted from cow or pig lungs, which raises supply, safety, and consistency concerns. A fully synthetic peptide-based alternative could eliminate animal sourcing, standardize production, and potentially expand access to a life-saving therapy — especially important for neonatal intensive care units worldwide.

Replacing animal-derived biological products with synthetic peptides is a recurring theme in medicine — from insulin to lung surfactant. KL4 represents a proof of concept that synthetic peptides can reproduce complex biological functions in the lungs. Understanding how its adaptive structure works could inform design of next-generation surfactant peptides with improved properties, and the synthetic approach could make surfactant therapy more accessible in resource-limited settings where animal-derived products are expensive or unavailable.

This is a review focused on one peptide (KL4) and its structural mechanism. Clinical comparison data between synthetic and animal-derived surfactants across different patient populations is limited. The molecular characterization is detailed but translating structural insights to improved clinical formulations remains an ongoing challenge.